zanubrutinib · Brukinsa
Small molecule
Evidence outlook
Approved: Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (4)
- Adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen
- Treatment of chronic lymphocytic leukemia (including small lymphocytic lymphoma), Waldenström's macroglobulinemia, and lymphoplasmacytic lymphoma
- Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). Brukinsa in combination with obinutuzumab is indicated for the treatment of...
- Adult patients with relapsed/refractory mantle cell lymphoma who have received at least one prior therapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05976763 NCT05976763 · Mantle Cell Lymphoma Registry: NCT05976763 | 3 | Progression-free survival (PFS) 1 (Arm A) (Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years); Progression-free survival (PFS) 2 (Arm B) (Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years) 2038-08-31 | In progress: results expected 31 Aug 2038 | not yet graded | link ↗ |
View 3 more trials
NCT03206970 NCT03206970 · Mantle Cell Lymphoma All 86 participants received zanubrutinib, with no randomization, no blinding and no comparison group. The response rate cleared a fixed benchmark of 40%, but without a control group the study cannot show how much of the result is due to the drug. Registry: NCT03206970 | 2 | Overall Response Rate (ORR) As Assessed By Independent Review Committee (Up to 1 year and 11 months) 2019-02-15 | Overall response rate by independent review: 72/86 (83.7%, 95% CI 74.2 to 90.8), p<0.0001 against a null rate of 40% (single arm) (CT.gov posted results). | Weak signal | link ↗ |
NCT02343120 NCT02343120 · B-cell Malignancies Every participant received zanubrutinib, with no comparison group, no randomization and no blinding. The main outcomes were side effects and the dose to carry forward, so the study did not test whether the drug works better than another treatment. Registry: NCT02343120 | 1/2 | Part 1 and Part 2: Number of Participants With Adverse Events (Up to approximately 6 years and 7 months); Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib (Month 9) 2021-03-31 | First-in-human Phase 1/2, 385 patients with B-cell malignancies: treatment-emergent adverse events 274/278 (160 mg twice daily) and 94/95 (320 mg once daily); recommended Phase 2 dose 320 mg daily from Part 1 dose escalation. Safety and dose-finding primaries with no formal test. | Weak signal | link ↗ |
MANGROVE NCT04002297 · Mantle Cell Lymphoma This was a randomized, open-label Phase 3 trial with 510 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-06-01. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate. Registry: NCT04002297 | 3 | Progression-free survival (PFS) determined by independent central review (Up to approximately 7 years) 2026-04-27 | Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (138)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Appears in other studies (6)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other BTK drugs
Acalabrutinib, Ibrutinib, Pirtobrutinib, rilzabrutinib. Compare all 5 BTK drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Mantle Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zanubrutinib (Brukinsa): this drug | Approved | Small molecule | BTK | Weak signal | NCT04002297: Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01). NCT03206970: Overall response rate by independent review: 72/86 (83.7%, 95% CI 74.2 to 90.8), p<0.0001 against a null rate of 40% (single arm) (CT.gov posted results). | |
| Acalabrutinib | Approved | Small molecule | BTK | Weak signal | NCT02213926: Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants | |
| Bortezomib | Approved | Small molecule | Proteasome | not yet graded | No reviewed efficacy summary in this indication | |
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | not yet graded | No reviewed efficacy summary in this indication | |
| Pirtobrutinib | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Rilzabrutinib | Approved(overall) | Small molecule | BTK | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Approved | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Phase 3 | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(103 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Brukinsa (zanubrutinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (12)
November 2026 (1)
What to watch
December 2026 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (30)
February 2027 (3)
What to watch
What to watch
What to watch
March 2027 (2)
April 2027 (3)
What to watch
What to watch
What to watch
May 2027 (2)
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (2)
August 2027 (1)
What to watch
October 2027 (3)
What to watch
What to watch
What to watch
November 2027 (2)
December 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (29)
January 2028 (1)
What to watch
February 2028 (2)
What to watch
What to watch
March 2028 (2)
April 2028 (2)
May 2028 (3)
What to watch
What to watch
What to watch
June 2028 (1)
What to watch
July 2028 (2)
August 2028 (3)
What to watch
What to watch
What to watch
September 2028 (2)
October 2028 (2)
December 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (18)
January 2029 (3)
What to watch
What to watch
What to watch
March 2029 (2)
April 2029 (2)
May 2029 (2)
June 2029 (1)
What to watch
July 2029 (1)
What to watch
November 2029 (2)
December 2029 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2030 (5)
February 2030 (1)
What to watch
March 2030 (2)
April 2030 (1)
What to watch
July 2030 (1)
What to watch
2031 (3)
February 2031 (1)
What to watch
March 2031 (1)
What to watch
April 2031 (1)
What to watch
2032 (3)
January 2032 (1)
What to watch
February 2032 (1)
What to watch
May 2032 (1)
What to watch
2034 (1)
April 2034 (1)
What to watch
2036 (1)
December 2036 (1)
What to watch
2038 (1)
August 2038 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent